Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular Pharmaceutics

• Publication date

  2017-07-13

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.molpharmaceut.7b00155PMID 28494151PMCID PMC7261408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• P-D3 Structural determinants for the selective Anti-HIV-1 activity of the all-beta alternative conformer of XCL1

  2016cited by this paper
• Structural Determinants for the Selective Anti-HIV-1 Activity of the All-β Alternative Conformer of XCL1

  2015cited by this paper
• AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

  2015cited by this paper
• Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance

  2015cited by this paper
• Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine

  2015cited by this paper
• Peptide entry inhibitors of enveloped viruses: The importance of interfacial hydrophobicity

  2014cited by this paper
• Visualization of Retroviral Envelope Spikes in Complex with the V3 Loop Antibody 447-52D on Intact Viruses by Cryo-Electron Tomography

  2014cited by this paper
• Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex

  2013cited by this paper
• Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16

  2013cited by this paper
• Inhibitors of HIV-1 entry.

  2013cited by this paper
• Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor

  2012cited by this paper
• Prediction of protein secondary structure from circular dichroism using theoretically derived spectra

  2012cited by this paper
• Peptides from Second Extracellular Loop of C-C Chemokine Receptor Type 5 (CCR5) Inhibit Diverse Strains of HIV-1*

  2012cited by this paper
• The conformation and orientation of a 27-residue CCR5 peptide in a ternary complex with HIV-1 gp120 and a CD4-mimic peptide.

  2011cited by this paper
• Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists

  2010cited by this paper
• BMC Structural Biology BioMed Central

  2008cited by this paper
• K2D2: Estimation of protein secondary structure from circular dichroism spectra

  2008cited by this paper
• A Monoclonal Fab Derived from a Human Nonimmune Phage Library Reveals a New Epitope on gp41 and Neutralizes Diverse Human Immunodeficiency Virus Type 1 Strains

  2007cited by this paper
• Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4

  2007cited by this paper
• Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

  2007cited by this paper
• Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.

  2006cited by this paper
• A Tyrosine-sulfated Peptide Derived from the Heavy-chain CDR3 Region of an HIV-1-neutralizing Antibody Binds gp120 and Inhibits HIV-1 Infection*

  2006cited by this paper
• Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

  2005cited by this paper
• Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

  2005cited by this paper
• Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth.

  2005cited by this paper
• Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

  2005cited by this paper
• Structure of a V3-Containing HIV-1 gp120 Core

  2005cited by this paper
• Cryptic Nature of a Conserved, CD4-Inducible V3 Loop Neutralization Epitope in the Native Envelope Glycoprotein Oligomer of CCR5-Restricted, but Not CXCR4-Using, Primary Human Immunodeficiency Virus Type 1 Strains

  2005cited by this paper
• Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.

  2004cited by this paper
• The HIV Env-mediated fusion reaction.

  2003cited by this paper
• Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base

  2003cited by this paper
• Mechanisms of viral membrane fusion and its inhibition.

  2001cited by this paper
• Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set.

  2000cited by this paper
• Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).

  1999cited by this paper
• The antigenic structure of the HIV gp120 envelope glycoprotein

  1998cited by this paper
• Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

  1998cited by this paper
• Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding

  1995cited by this paper
• A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B

  1995cited by this paper
• Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

  1994cited by this paper
• Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding

  1993cited by this paper
• Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

  1991cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Development of Synthetic Approaches Towards HIV Integrase Strand Transfer Inhibitors (INSTIs)

  2022cites this paper
• Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors

  2020cites this paper
• Peptides to combat viral infectious diseases

  2020cites this paper
• Drug Re‐positioning Studies for Novel HIV‐1 Inhibitors Using Binary QSAR Models and Multi‐target‐driven In Silico Studies

  2020cites this paper
• Application of Multiscale Simulation Tools on GPCRs. An Example with Angiotensin II Type 1 Receptor.

  2018cites this paper
• The CCR5-∆32 Mutation: Impact on Disease Outcome in Individuals with Hepatitis B Infection in the Southern Khorasan Population (East of Iran)

  2017cites this paper
• The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection

  2017cites this paper